SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Option Care Health, Inc. (OPCH) trades at a trailing P/E of 22.2, forward P/E of 15.0. Trailing earnings yield is 4.51%, forward earnings yield 6.68%. PEG 5.41. Graham Number is $15.74.
Criteria proven by this page:
- VALUE (64/100, Pass) — P/E is below market average (22.2); analyst target implies upside (+36.7%); earnings yield beats bond yields (4.51%).
- Forward P/E 15.0 (down from trailing 22.2) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 5.41 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 4.51% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 6.68% as earnings recover.
- Analyst consensus target $38.14 (+36.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 67/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
64/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — OPCH
Valuation Multiples
P/E (TTM)22.2
Forward P/E15.0
PEG Ratio5.41
Forward PEG0.33
P/B Ratio3.47
P/S Ratio0.82
EV/EBITDA9.5
Per Share Data
EPS (TTM)$1.31
Forward EPS (Est.)$1.87
Book Value / Share$8.39
Revenue / Share$35.73
FCF / Share$1.52
Yields & Fair Value
Earnings Yield4.51%
Forward Earnings Yield6.68%
Dividend Yield0.00%
Graham Number$15.74
SharesGrow IV$55.58 (+99.2%)
Analyst Target$38.14 (+36.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-2.3 |
0.03 |
-3.09 |
0.10 |
- |
| 2017 |
-5.6 |
-0.40 |
-4.44 |
0.44 |
- |
| 2018 |
-74.7 |
3.77 |
-3.17 |
0.24 |
- |
| 2019 |
-30.7 |
0.44 |
2.57 |
1.01 |
0.09% |
| 2020 |
-350.5 |
3.86 |
2.79 |
0.93 |
- |
| 2021 |
36.6 |
-0.02 |
4.35 |
1.49 |
- |
| 2022 |
36.2 |
5.65 |
3.93 |
1.38 |
- |
| 2023 |
22.6 |
0.28 |
4.24 |
1.40 |
- |
| 2024 |
18.8 |
-1.08 |
2.83 |
0.80 |
- |
| 2025 |
24.3 |
5.98 |
3.80 |
0.89 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-1.77 |
$935.59M |
$-41.51M |
-4.4% |
| 2017 |
$-2.02 |
$817.19M |
$-62.61M |
-7.7% |
| 2018 |
$-1.62 |
$708.9M |
$-51.69M |
-7.3% |
| 2019 |
$-0.49 |
$2.31B |
$-75.92M |
-3.3% |
| 2020 |
$-0.04 |
$3.03B |
$-8.08M |
-0.3% |
| 2021 |
$0.77 |
$3.44B |
$139.9M |
4.1% |
| 2022 |
$0.83 |
$3.94B |
$150.56M |
3.8% |
| 2023 |
$1.48 |
$4.3B |
$267.09M |
6.2% |
| 2024 |
$1.23 |
$5B |
$211.82M |
4.2% |
| 2025 |
$1.28 |
$5.65B |
$207.59M |
3.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$1.87 |
$1.83 – $1.91 |
$5.94B |
$5.88B – $5.99B |
8 |
| 2027 |
$2.13 |
$2.08 – $2.21 |
$6.45B |
$6.35B – $6.54B |
8 |
| 2028 |
$2.44 |
$2.43 – $2.45 |
$7.03B |
$7.02B – $7.03B |
3 |
| 2029 |
$2.57 |
$2.53 – $2.61 |
$7.61B |
$7.52B – $7.7B |
1 |
| 2030 |
$2.85 |
$2.81 – $2.90 |
$8.33B |
$8.23B – $8.43B |
1 |
